Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation ...

Boosting levels of a deficient protein has clear survival benefits for people with the genetic condition alpha-1 antitrypsin deficiency (AATD), according to new research led by RCSI University of ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation for KB408 for the treatment of alpha-1 antitrypsin deficiency, according ...

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the misfolding and accumulation of the mutant variant of alpha-1 antitrypsin (AAT) within hepatocytes, which limits its ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Least-squares mean percent differences in serum Z-AAT ...

Chronic obstructive pulmonary disease (COPD) remains highly prevalent among veterans, but the contribution of alpha-1 antitrypsin deficiency (AAT deficiency or AATD) to this patient population remains ...

Sanofi is buying Inhibrx for US$1.7 billion plus nearly $300 million in potential milestones. The deal is focused on INBRX-101, an enzyme replacement therapy that is currently in phase II trials for ...

Korro Bio, Inc. announced that its investigational drug KRRO-110 has received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD). This designation highlights the ...